Opthea Ltd
ASX:OPT
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Opthea Ltd
Common Shares Outstanding
Opthea Ltd
Common Shares Outstanding Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Common Shares Outstanding | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Opthea Ltd
ASX:OPT
|
Common Shares Outstanding
$1.4B
|
CAGR 3-Years
37%
|
CAGR 5-Years
32%
|
CAGR 10-Years
25%
|
|
|
Mesoblast Ltd
ASX:MSB
|
Common Shares Outstanding
$1.3B
|
CAGR 3-Years
18%
|
CAGR 5-Years
17%
|
CAGR 10-Years
13%
|
|
|
CSL Ltd
ASX:CSL
|
Common Shares Outstanding
$482.1m
|
CAGR 3-Years
0%
|
CAGR 5-Years
1%
|
CAGR 10-Years
0%
|
|
|
Race Oncology Ltd
ASX:RAC
|
Common Shares Outstanding
AU$180.8m
|
CAGR 3-Years
4%
|
CAGR 5-Years
7%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
Common Shares Outstanding
AU$338.8m
|
CAGR 3-Years
2%
|
CAGR 5-Years
4%
|
CAGR 10-Years
N/A
|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
Common Shares Outstanding
AU$597.2m
|
CAGR 3-Years
-43%
|
CAGR 5-Years
-28%
|
CAGR 10-Years
-12%
|
|
Opthea Ltd
Glance View
Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. The company is headquartered in Melbourne, Victoria. The firm is engaged in developing and commercializing therapies primarily for eye diseases. The firm's lead product candidate OPT-302, is a soluble form of vascular endothelial growth factors-3 (VEGFR 3) in clinical development as a therapy for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). The firm's technology platform focuses on vascular endothelial growth factors, such as VEGF C, VEGF D and VEGF Receptor 3 for the treatment of diseases associated with blood and lymphatic vessel growth (angiogenesis and lymphangiogenesis), as well as vascular leakage. The company has also conducted various activities to support its clinical development programs in wet AMD and DME, including clinical data analysis and manufacturing of OPT-302 for use in Phase III clinical trials.
See Also
What is Opthea Ltd's Common Shares Outstanding?
Common Shares Outstanding
1.4B
USD
Based on the financial report for Dec 31, 2025, Opthea Ltd's Common Shares Outstanding amounts to 1.4B USD.
What is Opthea Ltd's Common Shares Outstanding growth rate?
Common Shares Outstanding CAGR 10Y
25%
Over the last year, the Common Shares Outstanding growth was 11%. The average annual Common Shares Outstanding growth rates for Opthea Ltd have been 37% over the past three years , 32% over the past five years , and 25% over the past ten years .
